English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Giant cell bone tumors (GCTs) are rare benign borderline tumors, diagnosed mainly in 30 years old young women [1]. They make up 5% of primary bone neoplasms and 20% of all benign bone tumors [2, 3]. Although it is composed of mature tumor cells, distant metastases, most commonly lung (1% -5%), are found in 2% of clinical cases [4-6]. In the area of the tumor there is local pain with soft tissue edema, combined with reduced motor activity, and in large inoperable tumors severe neurological pathology [7]. 50% of the GCTs are located near the knee in the distal femur or proximal tibia, and 10% in the sacral region and vertebrae. Sacral GCTs are the third most common axially growing neoplasms [6, 8-14]. Due to the rare diagnosis of sacral GCTs and the relatively small number of clinical cases treated with different methods, the treatment of these tumors is controversial [15]. This article discusses a complex treatment approach for giant cell bone tumors, focusing on the indications for radiotherapy combined with targeted therapy.

medical and clinical research

Combined with Targeted Therapy Intensively Modulated Radiotherapy for Inoperable Giant Cell Sacral Tumor – Three - Year Follow-up of a Rare Borderline Tumor with Literature Review